The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain

European Journal of Pharmacology

Volumn 460, Issue 2-3, 2003, Pages 109-116

  Blackburn Munro, Gordon ^a   Jensen, Bo Skaaning ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

Anticonvulsant; Chronic constriction injury; Formalin test; Neuropathic pain; Spared nerve injury; Tail flick

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; ANTICONVULSIVE AGENT; CHLOROETHANE; KETONE DERIVATIVE; RETIGABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COLD SENSITIVITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FOOT; LATENT PERIOD; MALE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRICK TEST; PRIORITY JOURNAL; RAT; TAIL; THERMAL STIMULATION;

EID: 0037462422     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02924-2     Document Type: Article

References (38)

1. Alaburda A., Perrier J.F., Hounsgaard J. An M-like outward current regulates the excitability of spinal motoneurones in the adult turtle. J. Physiol. 540:2002;875-881.
2. Backonja M. Anticonvulsants and antiarrhythmics in the treatment of neuropathic pain syndromes. Hansson P.T., Fields H.L., Hill R.G. Neuropathic Pain: Pathophysiology and Treatment. Progress in Pain Research and Management. 2001;185-201 IASP Press, Seattle.
3. + channels in pain pathways. Trends Pharmacol. Sci. 22:2001;27-31.
4. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 33:1988;87-107.
5. + channel blockers in the formalin test. Eur. J. Pharmacol. 445:2002;225-232.
6. Brown B.S., Yu S.P. Modulation and genetic identification of the M channel. Prog. Biophys. Mol. Biol. 73:2000;135-166.
7. Chaplan S.R., Malmberg A.B., Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J. Pharmacol. Exp. Ther. 280:1997;829-838.
8. Decosterd I., Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 87:2000;149-158.
9. Devor M., Seltzer Z. Pathophysiology of damaged nerves in relation to chronic pain. Wall P.D., Melzack R. Textbook of Pain. 1999;129-164 Churchill Livingstone, London.
10. Dickenson A.H., Sullivan A.F. Subcutaneous formalin induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain. 30:1987;349-360.
11. Eglen R.M., Hunter J.C., Dray A. Ions in the fire: recent ion-channel research and approaches to pain therapy. Trends Pharmacol. Sci. 20:1999;337-342.
12. Erichsen H.K., Blackburn-Munro G. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain. 98:2002;151-161.
13. + channel blockers in two rat models of neuropathic pain. Eur. J. Pharmacol. 458:2003;275-282.
14. Friedel H.A., Fitton A. Flupirtine: a review of its analgesic properties, and therapeutic efficacy in pain states. Drug. 45:1993;548-569.
15. + currents in adult rat sensory neurons. J. Neurophysiol. 75:1996;2629-2646.
16. + current in nociceptors. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1108-1112.
17. Hunter J.C., Gogas K.R., Hedley L.R., Jacobson L.O., Kassotakis L., Thompson J., Fontana D.J. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur. J. Pharmacol. 324:1997;153-160.
18. Ishikawa K., Tanaka M., Black J.A., Waxman S.G. Changes in expression of voltage-gated potassium channels in dorsal root ganglion neurons following axotomy. Muscle Nerve. 22:1999;502-507.
19. Jentsch T.J. Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev., Neurosci. 1:2000;21-30.
20. Kapetanovic I.M., Rundfeldt C. D-23129: a new anticonvulsant compound. CNS Drug Rev. 2:1996;308-311.
21. Karchewski L.A., Burbridge S.A., Woolf C.J. Localization of KCNQ potassium channels in primary sensory neurons. Abstr. - Soc. Neurosci. 819.8:2001.
22. 2 using microdialysis in conscious rats. Br. J. Pharmacol. 114:1995;1069-1075.
23. Rasband M.N., Park E.W., Vanderah T.W., Lai J., Porreca F., Trimmer J.S. Distinct potassium channels on pain-sensing neurons. Proc. Natl. Acad. Sci. U. S. A. 23:2001;13373-13378.
24. + channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 23:2000;393-398.
25. Rundfeldt C., Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci. Lett. 282:2000;73-76.
26. Selyanko A.A., Passmore G.M., Brown T.A., Burbidge S.A., Main M., Brown D.A. Identification and nociceptive significance of M-current in small dorsal root ganglion neurones. Abstr. - Soc. Neurosci. 272.21:2001.
27. Seyfried J., Evert B.O., Rundfeldt C., Schulz J.B., Kovar K.A., Klockgether T., Wullner U. Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. Eur. J. Pharmacol. 400:2000;155-166.
28. Tatulian L., Delmas P., Abogadie F.C., Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. 21:2001;5535-5545.
29. Tober C., Rostock A., Rundfeldt C., Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 15:1996;163-169.
30. Wang H.S., Brown B.S., McKinnon D., Cohen I.S. Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol. Pharmacol. 57:2000;1218-1223.
31. Wang H., Sun H., Della Penna K., Benz R.J., Xu J., Gerhold D.L., Holder D.J., Koblan K.S. Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience. 114:2002;529-546.
32. Waxman S.G. The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain. S6:1999;S133-S140.
33. Wickenden A.D., Zou A., Wagoner P.K., Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br. J. Pharmacol. 132:2001;381-384.
34. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science. 288:2000;1765-1769.
35. Yashpal K., Fisher K., Chabot J.-G., Coderre T.J. Differential effects of NMDA and group I mGluR anatgonists on both nociception and spinal cord protein kinase C translocation in the formalin test and a model of neuropathic pain in rats. Pain. 94:2001;17-29.
36. Zaczek R., Chorvat R.J., Saye J.A., Pierdomenico M.E., Maciag C.M., Logue A.R., Fisher B.N., Rominger D.H., Earl R.A. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J. Pharmacol. Exp. Ther. 285:1998;724-730.
37. Zimmerman M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.
38. Zimmerman M. Pathobiology of neuropathic pain. Eur. J. Pharmacol. 429:2001;23-37.